Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.85
BGMD's Cash to Debt is ranked higher than
63% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. BGMD: 1.85 )
BGMD' s 10-Year Cash to Debt Range
Min: 0.68   Max: No Debt
Current: 1.85

Equity to Asset 0.35
BGMD's Equity to Asset is ranked higher than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. BGMD: 0.35 )
BGMD' s 10-Year Equity to Asset Range
Min: -12.54   Max: 0.88
Current: 0.35

-12.54
0.88
F-Score: 4
Z-Score: -20.13
M-Score: -1.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -240.57
BGMD's Operating margin (%) is ranked higher than
52% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. BGMD: -240.57 )
BGMD' s 10-Year Operating margin (%) Range
Min: -1783.39   Max: -69.34
Current: -240.57

-1783.39
-69.34
Net-margin (%) -267.64
BGMD's Net-margin (%) is ranked higher than
51% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. BGMD: -267.64 )
BGMD' s 10-Year Net-margin (%) Range
Min: -2095.48   Max: -78.43
Current: -267.64

-2095.48
-78.43
ROE (%) -1118.51
BGMD's ROE (%) is ranked lower than
57% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. BGMD: -1118.51 )
BGMD' s 10-Year ROE (%) Range
Min: -224.23   Max: -224.23
Current: -1118.51

ROA (%) -84.81
BGMD's ROA (%) is ranked lower than
54% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. BGMD: -84.81 )
BGMD' s 10-Year ROA (%) Range
Min: -174.66   Max: -67.46
Current: -84.81

-174.66
-67.46
ROC (Joel Greenblatt) (%) -5425.97
BGMD's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.66 vs. BGMD: -5425.97 )
BGMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9127.71   Max: -327.37
Current: -5425.97

-9127.71
-327.37
Revenue Growth (%) -18.80
BGMD's Revenue Growth (%) is ranked higher than
56% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. BGMD: -18.80 )
BGMD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -18.8
Current: -18.8

EBITDA Growth (%) -51.50
BGMD's EBITDA Growth (%) is ranked higher than
52% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. BGMD: -51.50 )
BGMD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -40.2
Current: -51.5

EPS Growth (%) -54.40
BGMD's EPS Growth (%) is ranked higher than
50% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. BGMD: -54.40 )
BGMD' s 10-Year EPS Growth (%) Range
Min: 0   Max: -41.3
Current: -54.4

» BGMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

BGMD Guru Trades in Q4 2012

Chuck Royce Sold Out
» More
Q4 2013

BGMD Guru Trades in Q4 2013

Paul Tudor Jones 27,645 sh (New)
» More
Q1 2014

BGMD Guru Trades in Q1 2014

Paul Tudor Jones 11,879 sh (-57.03%)
» More
Q2 2014

BGMD Guru Trades in Q2 2014

Paul Tudor Jones 11,879 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BGMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.70
BGMD's P/B is ranked higher than
69% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. BGMD: 3.70 )
BGMD' s 10-Year P/B Range
Min: 2.56   Max: 141.5
Current: 3.7

2.56
141.5
P/S 3.40
BGMD's P/S is ranked higher than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.86 vs. BGMD: 3.40 )
BGMD' s 10-Year P/S Range
Min: 2.92   Max: 121
Current: 3.4

2.92
121
EV-to-EBIT -1.24
BGMD's EV-to-EBIT is ranked higher than
53% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BGMD: -1.24 )
BGMD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.24

Current Ratio 1.68
BGMD's Current Ratio is ranked higher than
57% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. BGMD: 1.68 )
BGMD' s 10-Year Current Ratio Range
Min: 0.3   Max: 7.97
Current: 1.68

0.3
7.97
Quick Ratio 1.60
BGMD's Quick Ratio is ranked higher than
60% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. BGMD: 1.60 )
BGMD' s 10-Year Quick Ratio Range
Min: 0.3   Max: 7.96
Current: 1.6

0.3
7.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.43
BGMD's Price/Net Cash is ranked higher than
90% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BGMD: 6.43 )
BGMD' s 10-Year Price/Net Cash Range
Min: 3.14   Max: 368
Current: 6.43

3.14
368
Price/Net Current Asset Value 5.63
BGMD's Price/Net Current Asset Value is ranked higher than
90% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BGMD: 5.63 )
BGMD' s 10-Year Price/Net Current Asset Value Range
Min: 3.11   Max: 184
Current: 5.63

3.11
184
Price/Tangible Book 4.09
BGMD's Price/Tangible Book is ranked higher than
73% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.91 vs. BGMD: 4.09 )
BGMD' s 10-Year Price/Tangible Book Range
Min: 2.84   Max: 92
Current: 4.09

2.84
92
Price/Median PS Value 0.21
BGMD's Price/Median PS Value is ranked higher than
98% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.27 vs. BGMD: 0.21 )
BGMD' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 7.24
Current: 0.21

0.34
7.24

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:RBM.Germany
BG Medicine is a life sciences company engaged into discovery, development, and commercialization of novel diagnostic tests based on biomarkers. Its tests include BGM Galectin-3, CardioSCORE.
» More Articles for BGMD

Headlines

Articles On GuruFocus.com
comment on BGMD Jun 09 2011 

More From Other Websites
Most active Nasdaq-traded stocks Oct 20 2014
Nasdaq stocks posting largest volume increases Oct 17 2014
BG MEDICINE, INC. Files SEC form 8-K, Other Events Oct 17 2014
BG MEDICINE, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Notice of... Sep 11 2014
BG MEDICINE, INC. Financials Aug 22 2014
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 14 2014
BG Medicine Reports Second Quarter 2014 Financial Results Aug 14 2014
Q2 2014 BG Medicine Inc Earnings Release - Before Market Open Aug 14 2014
BG Medicine Announces Q2 2014 Financial Results Release Date and Conference Call Information Aug 07 2014
BG MEDICINE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 05 2014
5 Stocks Under $10 Set to Soar May 29 2014
Covance Expands in Market Access May 20 2014
Why BG Medicine (BGMD) Stock Is Plunging Today May 14 2014
BG Medicine's (BGMD) CEO, Paul Sohmer on Q1 2014 Results - Earnings Call Transcript May 14 2014
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... May 14 2014
BG Medicine reports Q1 EPS (8c), one estimate (8c) May 14 2014
BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Apr 03 2014
Why BG Medicine (BGMD) Is Tumbling on Thursday Apr 03 2014
BG MEDICINE, INC. Files SEC form 10-K, Annual Report Mar 27 2014
Publication Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction of Near-Term... Mar 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK